The report notes a long buildup in Sun Pharma with price up 0.47% and OI up 5.15%.
Read this note →Sun Pharmaceutical Industries Limited
NSE SUNPHARMA BSE 524715 INE044A01036
0 filings · 0 analysed
1,904.50
+7.39%
over 5 days
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing.
Targets, and what happened next
What each house published, and where the price has gone since. Orivam issues no calls of its own and takes no view on these.
| House | Published | Call | Entry | Target | Now | Progress | Standing |
|---|---|---|---|---|---|---|---|
| HDFC Securities | 31 Oct 2026, 06:41 | long | 1,777.70 | 2,180.00 | 1,860.00 | 20% | open by 2027-10-31 |
| HDFC Securities | 07 Oct 2026, 15:25 | long | 1,781.00 | 2,320.00 | 1,860.00 | 15% | open by 2027-10-07 |
| Motilal Oswal Financial Services Ltd. | 29 Sep 2026, 08:49 | long | 1,865.00 | 2,310.00 | 1,860.00 | -1% | open by 2027-09-29 |
Deadlines: 0 stated by the house, the rest set by Orivam’s convention — ten trading days for a technical call, twelve months for a price target. A target with no date cannot be judged, so one has to be chosen.
What the desks said
The report says EBITDA grew 14% YoY on 12% sales growth, retains BUY and cuts FY27E/28E EPS by 4%/2% while revising target price to INR 2,180.
Read this note →The note reports Sun Pharma approved a forensic audit into an alleged fund misappropriation case and launched a probe into suspected employee fraud.
Read this note →The report notes Sun Pharma approved a plan to raise up to Rs 10,000 crore via NCDs for funding and business expansion.
Read this note →The report expects 11% YoY revenue growth driven by specialty scale-up and India growth, with EBITDA margin improving on cost controls.
Read this note →The note says Sun Pharmaceutical established the Sun Professorship in Dermatology at the Icahn School of Medicine at Mount Sinai.
Read this note →The report lists Sun Pharma as a breakdown stock at a one-month low, down 1.79%.
Read this note →The report expects SUN's US sales to dip 12% YoY due to lower generic Lenalidomide sales, with overall sales growth of 8.5% YoY.
Read this note →The note mentions Sun Pharma gained following the US tariff exemption news for pharma products.
Read this note →The report reiterates a Buy rating on Sun Pharma with a target price of INR 2,310 (26% upside), citing tariff exemptions for specialty drugs and European approval of its PCSK9 inhibitor.
Read this note →The report states Sun Pharma signed an exclusive licensing agreement with LIB Therapeutics for lerodalcibep, excluding the US and China markets.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief